BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer Treatment

Reuters08-22

BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Aug 22 (Reuters) - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:

SAYS UNIT RECEIVES "STUDY MAY PROCEED LETTER" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENT

Source text

Further company coverage: 002675.SZ

(Reporting by Hong Kong newsroom)

((donny.kwok@thomsonreuters.com; +852 3462 7745;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2561644249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561644249","market":"fut","top_or_hot":-1,"title":"BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a></title></head><body><p><span>Aug 22 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/002675\">Yantai Dongcheng Biochemicals</a> Co Ltd <span>002675.SZ</span>:</p><ul><li><p>SAYS UNIT RECEIVES \"STUDY MAY PROCEED LETTER\" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENT</p></li></ul><p>Source text</p><p>Further company coverage: <span>002675.SZ</span></p><p> (Reporting by Hong Kong newsroom)</p><p> ((donny.kwok@thomsonreuters.com; +852 3462 7745;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-22 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a></title></head><body><p><span>Aug 22 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/002675\">Yantai Dongcheng Biochemicals</a> Co Ltd <span>002675.SZ</span>:</p><ul><li><p>SAYS UNIT RECEIVES \"STUDY MAY PROCEED LETTER\" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENT</p></li></ul><p>Source text</p><p>Further company coverage: <span>002675.SZ</span></p><p> (Reporting by Hong Kong newsroom)</p><p> ((donny.kwok@thomsonreuters.com; +852 3462 7745;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002675","symbol_name":"东诚药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nL4N3UE09J:1","article_id":"2561644249","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561644249","pubTimestamp":1755835218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer TreatmentAug 22  - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:SAYS UNIT RECEIVES \"STUDY MAY PROCEED LETTER\" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENTSource textFurther company coverage: 002675.SZ  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002675":"东诚药业","BK0239":"医药制造"},"translate_title":"简介-烟台单位Ac-LNC1011治疗前列腺癌临床试验获得美国FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002675":0.9},"content_text":"BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer TreatmentAug 22 (Reuters) - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:SAYS UNIT RECEIVES \"STUDY MAY PROCEED LETTER\" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENTSource textFurther company coverage: 002675.SZ (Reporting by Hong Kong newsroom) ((donny.kwok@thomsonreuters.com; +852 3462 7745;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2561644249","isCrawlerRequest":true}